Dr. Nicholas Jacob serves as Chief Scientific Officer of ARMR Sciences Inc., where he leads scientific strategy and platform development across the company’s preventive biologics pipeline targeting synthetic drug threats. He directs translational research, IND-enabling studies, regulatory strategy, and external scientific partnerships, advancing licensed academic innovations into IND-ready and clinical-stage assets while maintaining rigorous GMP and quality standards. He also shapes long-term R&D strategy, secures non-dilutive federal funding, contributes to intellectual property development, and serves as the company’s primary scientific representative to stakeholders and investors.

Prior to ARMR, Dr. Jacob led development of a monoclonal antibody against fentanyl from academic discovery through successful IND filing in July 2023, coordinating global CMC and nonclinical programs across CROs and CDMOs and contributing to PIND and IND submissions. He played a significant role in securing more than $20 million in NIDA funding to support clinical advancement.

He is also Co-Founder of Decode Bio, Inc., where he helped develop a microfluidic, picoliter, optically encoded screening platform for oncology drug discovery and supported investor diligence, fundraising strategy, licensing, and academic partnerships. In addition, he founded Gaston Works, LLC, advising biotechnology companies on translational development strategy, CRO/CDMO selection, and federal funding navigation across NIH, ARPA-H, DoD, and BARDA programs.

Dr. Jacob completed his doctoral training under Dr. Kim Janda at Scripps Research, where his work spanned addiction-focused biologics and first-in-class oncology therapeutics. He was instrumental in the structural reassignment of TIC10 (published in Angewandte Chemie), laying the foundation for the FDA-approved brain cancer therapy dordaviprone (Modeyso). His research has included bioconjugate vaccine design against fentanyl, nicotine, and cocaine; antibody engineering and biophysical characterization; immunogenicity optimization; and small-molecule probe development targeting TRAIL and MYC signaling pathways. He has authored multiple peer-reviewed publications across medicinal chemistry, immunopharmacology, and translational drug development.

Dr. Jacob earned his PhD in Chemical Biology from Scripps Research and his BS in Chemistry from the University of Rochester.